Drug Profile


Alternative Names: Epclusa; Fixed-dose combination of sofosbuvir and GS-5816 - Gilead Sciences; GS 5816/sofosbuvir; GS 7977/GS 5816; SOF/GS-5816; SOF/VEL; Sofosbuvir/GS 5816; Velpatasvir/sofosbuvir

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Carbamates; Chromans; Imidazoles; Naphthols; Phenylacetates; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 01 Aug 2017 Sofosbuvir/velpatasvir has a boxed warning in label regarding hepatitis B virus reactivation
  • 01 Aug 2017 The US FDA approves label update for sofosbuvir/velpatasvir to include patients co-infected with HIV
  • 28 Jul 2017 Gilead Sciences completes a phase II trial in Hepatitis C in Spain, Switzerland and United Kingdom (PO) (NCT02781571)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top